Donald R Branch

Donald R Branch, PhD

Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Affiliate Scientist, Toronto General Hospital Research Institute (TGHRI)
Keywords: signal transduction, cancer, transfusion medicine, HIV pathogenesis
Dr. Branch's current interests can be broken down into 4 main areas:
  • Signaling involving c-Src
  • Signaling in HIV/AIDS pathogenesis and disease resistance
  • Studies of SHP-1 tyrosine phosphatase in malignancies
  • Mechanism of intravenous immunoglobulin (IVIG) effect in autoimmune inflammatory diseases
Current projects include:
  • The function of pp60c-src and Pyk2 in HIV infection 
  • The role of signaling through the VPAC family of neuroendocrine receptors on HIV/AIDS infection and resistance to infection 
  • Drug discovery for small molecular weight molecules that block HIV fusion 
  • Identification of novel treatment modalities for HIV/AIDS 
  • The signaling pathways used by HIV for its early stages of its life cycle 
  • The mechanism of IVIG treatment for autoimmune inflammatory diseases 
  • Drug discovery for small molecular weight molecules that inhibit phagocytosis 
  • The mechanism of anti-D immune prophylaxis and treatment of idiopathic thrombocytopenic purpura
  • Drug discovery for alternatives to IVIG
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
J Immunol. 2018 Mar 12;:
Spirig R, Campbell IK, Koernig S, Chen CG, Lewis BJB, Butcher R, Muir I, Taylor S, Chia J, Leong D, Simmonds J, Scotney P, Schmidt P, Fabri L, Hofmann A, Jordi M, Spycher MO, Cattepoel S, Brasseit J, Panousis C, Rowe T, Branch DR, Baz Morelli A,...
Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure.
Eur J Haematol. 2018 Feb 17;:
Qadri SM, Donkor DA, Nazy I, Branch DR, Sheffield WP
ABO Zygosity, but not Secretor or Fc Receptor Status, is a Significant Risk Factor for IVIG-Associated Hemolysis.
Blood. 2018 Jan 05;:
Branch DR, Hellberg Å, Bruggeman CW, Storry JR, Sakac D, Blacquiere M, Tong TN, Burke-Murphy E, Binnington B, Parmar N, Sampson Riden L, Willie K, Armali C, Aziz J, Lieberman L, Laroche V, Callum J, Lin Y, Shehata N, Pavenski K, Lau W, Hannach B,...
IVIG regulates the survival of human but not mouse neutrophils.
Sci Rep. 2017 May 02;7(1):1296
Schneider C, Wicki S, Graeter S, Timcheva TM, Keller CW, Quast I, Leontyev D, Djoumerska-Alexieva IK, Käsermann F, Jakob SM, Dimitrova PA, Branch DR, Cummings RD, Lünemann JD, Kaufmann T, Simon HU, von Gunten S
The immune-stimulation capacity of liposome-treated red blood cells.
J Liposome Res. 2017 Mar 09;:1-9
da Silveira Cavalcante L, Branch DR, Duong TT, Yeung RS, Acker JP, Holovati JL
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis.
J Vis Exp. 2017 Jan 02;(119):
Tong TN, Branch DR
Ebola virus VP35 blocks stress granule assembly.
Virology. 2016 Dec 22;502:73-83
Le Sage V, Cinti A, McCarthy S, Amorim R, Rao S, Daino GL, Tramontano E, Branch DR, Mouland AJ
Shining a light on AHG "blind" spot(s).
Transfusion. 2016 Dec;56(12):2913-2915
Branch DR, Westhoff CM
Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice.
Blood. 2016 Sep 29;
Liu J, Santhanakrishnan M, Natarajan P, Gibb DR, Eisenbarth SC, Tormey CA, Siddon AJ, Stowell SR, Branch DR, Hendrickson JE
Optimal conditions for the performance of a monocyte monolayer assay.
Transfusion. 2016 Aug 21;
Tong TN, Burke-Murphy E, Sakac D, Pendergrast J, Cserti-Gazdewich C, Laroche V, Branch DR

Pages

 
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Affiliate Scientist, Toronto General Hospital Research Institute (TGHRI)

Associate Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
Scientist, Canadian Blood Services